Orgenesis (NASDAQ:ORGS – Get Free Report) is anticipated to issue its resultson Friday, August 7th. Analysts expect the company to announce earnings of ($2.60) per share and revenue of $2.80 million for the quarter.
Orgenesis Stock Performance
Shares of NASDAQ ORGS opened at $0.42 on Thursday. The stock has a market cap of $2.17 million, a P/E ratio of -0.04 and a beta of 3.14. The firm has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.39. Orgenesis has a 52-week low of $0.00 and a 52-week high of $1.00.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Featured Stories
- Five stocks we like better than Orgenesis
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
